Madrigal Pharmaceuticals, INC 8-K filings

Madrigal Pharmaceuticals announced the appointment of Dr. John C. Reed, a prominent biopharmaceutical research leader, to its Board of Directors, effective August 11, 2026.

Madrigal Pharmaceuticals announced robust second-quarter 2026 financial results, driven by a 71% year-over-year increase in Rezdiffra net sales to $364.3 million, with over 49,000 patients on the treatment.

Madrigal Pharmaceuticals stockholders approved the 2026 Stock Plan and 2026 Employee Stock Purchase Plan at the annual meeting, alongside a new Nonqualified Deferred Compensation Plan.

Madrigal Pharmaceuticals announced robust first-quarter 2026 financial results, driven by significant growth in Rezdiffra net sales and strategic pipeline expansion.

Madrigal Pharmaceuticals announced a reclassification of its Board of Directors to ensure a more equal distribution of members across its three classes.

Madrigal Pharmaceuticals announced robust fourth-quarter and full-year 2025 financial results, driven by nearly $1 billion in Rezdiffra sales and significant pipeline expansion.

Madrigal Pharmaceuticals has amended its agreement with Roche, gaining exclusive control over patent term extensions for its drug Rezdiffra in exchange for a delayed royalty reduction.

Madrigal Pharmaceuticals, Inc. announced the appointment of Rita Thakkar as Senior Vice President and Chief Accounting Officer, effective January 12, 2026.

Madrigal Pharmaceuticals announced robust third-quarter 2025 financial results, driven by strong Rezdiffra sales and strategic pipeline expansion.

Madrigal Pharmaceuticals reported strong second-quarter 2025 financial results driven by robust Rezdiffra sales, extended patent protection, and strategic pipeline advancements.

Madrigal Pharmaceuticals has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral GLP-1 receptor agonist, aiming to develop a best-in-class combination treatment for MASH with Rezdiffra.

Madrigal Pharmaceuticals has secured a $500 million senior secured credit facility from Blue Owl Capital to refinance existing debt and advance its metabolic dysfunction-associated steatohepatitis (MASH) pipeline.

Madrigal Pharmaceuticals, Inc. announced the successful re-election of four Class III directors, ratification of its independent auditor, and advisory approval of executive compensation and annual frequency for future compensation votes at its 2025 Annual Meeting of Stockholders.

Madrigal Pharmaceuticals announces first-quarter 2025 financial results, highlighted by $137.3 million in Rezdiffra net sales and positive clinical data updates.

Madrigal Pharmaceuticals' Chief Medical Officer, Dr. Rebecca Taub, will transition to a Senior Scientific and Medical Advisor role, effective April 21, 2025.

Madrigal Pharmaceuticals announced the appointment of Jacqualyn Fouse to its Board of Directors and the upcoming retirement of Fred Craves in July 2025.

Madrigal Pharmaceuticals announces strong Rezdiffra sales and promising two-year data demonstrating its potential benefit in patients with compensated MASH cirrhosis.

Madrigal Pharmaceuticals reports strong preliminary net sales for Q4 and full-year 2024 driven by Rezdiffra, with significant patient uptake and a solid cash position.

Madrigal Pharmaceuticals announced strong third-quarter 2024 financial results, highlighted by $62.2 million in net sales of Rezdiffra and significant progress in its clinical programs.

Madrigal Pharmaceuticals announced its second-quarter 2024 financial results, highlighted by $14.6 million in net sales of Rezdiffra and plans for European commercialization.

Madrigal Pharmaceuticals' stockholders approved an amendment to their 2015 stock plan, increasing the share pool by 750,000 shares and extending the plan's duration by 10 years.

Madrigal Pharmaceuticals has entered into a sales agreement with TD Securities to potentially sell up to $300 million of its common stock through an at-the-market offering.

Madrigal Pharmaceuticals announced its first-quarter 2024 financial results, highlighted by the FDA approval and launch of Rezdiffra for NASH, and a significant capital raise.

Madrigal Pharmaceuticals successfully closed the underwriter's option to purchase additional shares, raising approximately $86 million, bringing the total offering proceeds to around $660 million.

Madrigal Pharmaceuticals has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to generate approximately $574 million in net proceeds.

Madrigal Pharmaceuticals' Rezdiffra has been granted accelerated FDA approval as the first medication for adults with noncirrhotic NASH with moderate to advanced liver fibrosis.

Madrigal Pharmaceuticals has appointed Mardi C. Dier as its new Chief Financial Officer, effective March 11, 2024, while also announcing the departures of the current CFO and General Counsel.

Madrigal Pharmaceuticals reported its fourth quarter and full year 2023 financial results, highlighted by a strong cash position and the anticipation of its lead drug, resmetirom, receiving FDA approval for NASH.